Pharmaceutical supply chains get tangled in war with Iran

The Trump administration's military conflict with Iran is disrupting pharmaceutical supply chains and threatening to raise drug prices, particularly for medications dependent on petrochemicals. The effective closure of the Strait of Hormuz, a critical global shipping corridor, has driven up energy costs and created bottlenecks in the movement of raw materials needed for drug manufacturing. Pharmaceutical companies that rely on petrochemical inputs face rising production costs that could be passed on to consumers and insurers. The disruption is already affecting energy markets, with prices climbing as major shipping routes become inaccessible. Drug availability and affordability could worsen if the conflict continues and supply chain disruptions persist.